AnaptysBio, Inc.
NASDAQTotal Valuation
AnaptysBio, Inc. carries a market capitalization of 2.72B, placing it among publicly traded companies globally. Its enterprise value stands at 772.70M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 2.72B |
| Enterprise Value | 772.70M |
Share Statistics
AnaptysBio, Inc. currently has 29.03M shares outstanding.
| Shares Outstanding | 29.03M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 4.50, and the price-to-book ratio stands at -1.27.
| PE Ratio | N/A |
| PS Ratio | 4.50 |
| PB Ratio | -1.27 |
| P/TBV Ratio | 82.02 |
| P/FCF Ratio | 239.57 |
| P/OCF Ratio | 233.48 |
Enterprise Valuation
On an enterprise value basis, AnaptysBio, Inc. trades at an EV/EBITDA multiple of 17.88 and an EV/FCF ratio of 8.81. The EV/Sales ratio of 3.33 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 18.94 provides insight into valuation relative to core operating earnings.
| EV / Sales | 3.33 |
| EV / EBITDA | 17.88 |
| EV / EBIT | 18.94 |
| EV / FCF | 8.81 |
Financial Position
AnaptysBio, Inc. maintains a current ratio of 7.58, meaning it holds 7.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 106.79, indicating elevated leverage, while an interest coverage ratio of 0.52 demonstrates limited ability to service its debt obligations.
| Current Ratio | 7.58 |
| Quick Ratio | 7.49 |
| Debt / Equity | 106.79 |
| Debt / EBITDA | 0.31 |
| Interest Coverage | 0.52 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -7.13 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | -28.05 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
Over the trailing twelve months, AnaptysBio, Inc. has paid 160,000.00 in income taxes, reflecting an effective tax rate of 0.16.
| Income Tax | 160,000.00 |
| Effective Tax Rate | 0.16 |
Stock Price Statistics
AnaptysBio, Inc.'s stock has gained approximately 303.67882% over the past 52 weeks. The 50-day moving average sits at 60.00, while the 200-day moving average is 38.20.
| Beta (5Y) | N/A |
| 52-Week Price Change | 303.67882% |
| 50-Day Moving Average | 60.00 |
| 200-Day Moving Average | 38.20 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, AnaptysBio, Inc. generated 232.39M in revenue and converted that into -26.79M in net income, yielding earnings per share of -0.91. EBITDA reached 43.23M, while operating income came in at 40.80M.
| Revenue | 232.39M |
| Gross Profit | N/A |
| Operating Income | 40.80M |
| Pretax Income | -26.63M |
| Net Income | -26.79M |
| EBITDA | 43.23M |
| EBIT | 40.80M |
| Earnings Per Share (EPS) | -0.91 |
Balance Sheet
AnaptysBio, Inc. holds 286.46M in cash and equivalents against 13.61M in total debt, resulting in a net debt position of -248.47M. Total book value stands at -825.41M, with working capital of 274.41M providing operational flexibility.
| Cash & Cash Equivalents | 286.46M |
| Total Debt | 13.61M |
| Net Debt | -248.47M |
| Equity (Book Value) | -825.41M |
| Book Value Per Share | -29.19 |
| Working Capital | 274.41M |
Cash Flow
AnaptysBio, Inc. produced 4.48M in operating cash flow over the past twelve months. After subtracting -69,000.00 in capital expenditures, free cash flow totaled 4.41M - equivalent to 0.16 per share.
| Operating Cash Flow | 4.48M |
| Capital Expenditures | -69,000.00 |
| Free Cash Flow | 4.41M |
| FCF Per Share | 0.16 |
Margins
AnaptysBio, Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of 17.56 and net profit margin of -11.53 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | 17.56 |
| Pretax Margin | -11.46 |
| Profit Margin | -11.53 |
| EBITDA Margin | 18.60 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | 9.83 |
| FCF Yield | 0.42 |
Stock Splits
AnaptysBio, Inc.'s most recent stock split took place on April 20, 2026 with a 2:3 split ratio.
| Last Split Date | 4/20/2026 |
| Split Ratio | 2:3 |
Scores
AnaptysBio, Inc. posts an Altman Z-Score of 0.59, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 0.59 |